Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Avant Brands Inc. (AVNT.TO)
CAD0.65
+0.10 (+18.18%)
CA TSX Healthcare Drug Manufacturers - Specialty & Generic
Address
1632 Dickson Avenue V1Y 7T2
Kelowna, BC, CA
Kelowna, BC, CA
CEO
Norton Singhavon
Website
avantbrands.ca
IPO
2018-06-22
ISIN CA05353D2023
Also trades on
Other OTC · AVTBF (USD)
Toronto Stock Exchange · AVNT.TO (CAD)
Description
Avant Brands Inc. operates in Canada, focusing on the cultivation, production, and commercialization of high-quality cannabis products. The company provides both medical and recreational cannabis options, marketed under distinct brands including BLK MKT, Tenzo, GreenTec, cognoscente, Treehugger, and Pristine. Its distribution network encompasses medical and recreational retail channels, alongside an e-commerce website. Previously known as GTEC Holdings Ltd., the firm officially changed its name to Avant Brands Inc. in July 2021. Founded in 2017, Avant Brands Inc. is headquartered in Kelowna, Canada.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CAD0.65
+0.10 (+18.18%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7.9K
Beta
1.46
Float Shares
10.65M
Free Float %
93.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.17% | +14.04% | +25.00% | -23.53% | -18.75% | -27.78% | -20.73% | -85.56% | -96.56% | -98.45% | -98.45% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.65
Quality scores
Altman Z-Score
-2.72
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+0.3% Q1'26: +64.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+61.7% ★ Q1'26: -248.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-23.3% Q1'26: +2.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-40.1% Q1'26: -23.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-37.2% Q1'26: -37.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+13.8% Q1'26: +6.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-1.11× Q1'26: -1.17× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Nov 2019 actual |
Nov 2020 actual |
Nov 2021 actual |
Nov 2022 actual |
Nov 2023 actual |
Nov 2024 actual |
Nov 2026 1 Rev. Ana. 1 EPS Ana. |
Nov 2027 1 Rev. Ana. 1 EPS Ana. |
Nov 2028 1 Rev. Ana. 1 EPS Ana. |
Nov 2029 1 Rev. Ana. 1 EPS Ana. |
Nov 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.36M
est: 3.25M (-27.3%)
|
7.91M
est: 54.41M (-85.5%)
|
9.50M
est: 78.44M (-87.9%)
|
20.15M
est: 62.19M (-67.6%)
|
26.34M
est: 62.19M (-57.6%)
|
35.80M
est: 62.19M (-42.4%)
|
3.25M
3.25M – 3.25M
-94.8% YoY
|
54.41M
54.41M – 54.41M
+1,575.2% YoY
|
78.44M
78.44M – 78.44M
+44.2% YoY
|
62.19M
62.19M – 62.19M
-20.7% YoY
|
62.19M
62.19M – 62.19M
+0.0% YoY
|
| EBITDA |
-7.27M
est: -1.38M (-424.9%)
|
-5.27M
est: -23.19M (+77.3%)
|
-9.65M
est: -33.44M (+71.1%)
|
-1.89M
est: -26.51M (+92.9%)
|
4.53M
est: -26.51M (+117.1%)
|
-19.45M
est: -23.01M (+15.5%)
|
-1.20M
-1.20M – -1.20M
+94.8% YoY
|
-20.13M
-20.13M – -20.13M
-1,575.2% YoY
|
-29.02M
-29.02M – -29.02M
-44.2% YoY
|
-23.01M
-23.01M – -23.01M
+20.7% YoY
|
-23.01M
-23.01M – -23.01M
+0.0% YoY
|
| EBIT |
-8.30M
est: -1.87M (-343.6%)
|
-6.53M
est: -31.34M (+79.2%)
|
-10.91M
est: -45.18M (+75.8%)
|
-6.25M
est: -35.82M (+82.5%)
|
-1.76M
est: -35.82M (+95.1%)
|
-24.25M
est: -30.54M (+20.6%)
|
-1.59M
-1.59M – -1.59M
+94.8% YoY
|
-26.72M
-26.72M – -26.72M
-1,575.2% YoY
|
-38.52M
-38.52M – -38.52M
-44.2% YoY
|
-30.54M
-30.54M – -30.54M
+20.7% YoY
|
-30.54M
-30.54M – -30.54M
+0.0% YoY
|
| Net Income |
-9.77M
est: -11.79M (+17.1%)
|
-10.17M
est: 32.41M (-131.4%)
|
-11.23M
est: 50.09M (-122.4%)
|
-7.54M
est: 32.41M (-123.3%)
|
-5.07M
est: 32.41M (-115.6%)
|
-22.55M
est: 36.88M (-161.2%)
|
-13.41M
-13.41M – -13.41M
-136.4% YoY
|
36.88M
36.88M – 36.88M
+375.0% YoY
|
57.00M
57.00M – 57.00M
+54.5% YoY
|
36.88M
36.88M – 36.88M
-35.3% YoY
|
36.88M
36.88M – 36.88M
+0.0% YoY
|
| SGA |
8.62M
est: 1.41M (+510.4%)
|
4.14M
est: 23.66M (-82.5%)
|
5.25M
est: 34.10M (-84.6%)
|
9.46M
est: 27.04M (-65.0%)
|
10.00M
est: 27.04M (-63.0%)
|
8.90M
est: 22.73M (-60.8%)
|
1.19M
1.19M – 1.19M
-94.8% YoY
|
19.89M
19.89M – 19.89M
+1,575.2% YoY
|
28.67M
28.67M – 28.67M
+44.2% YoY
|
22.73M
22.73M – 22.73M
-20.7% YoY
|
22.73M
22.73M – 22.73M
+0.0% YoY
|
| EPS |
-2.85
est: -1.20 (-137.5%)
|
-2.17
est: 3.30 (-165.8%)
|
-1.80
est: 5.10 (-135.3%)
|
-1.20
est: 3.30 (-136.4%)
|
-0.61
est: 3.30 (-118.5%)
|
-2.30
est: 3.30 (-169.7%)
|
-1.20
-1.20 – -1.20
-136.4% YoY
|
3.30
3.30 – 3.30
+375.0% YoY
|
5.10
5.10 – 5.10
+54.5% YoY
|
3.30
3.30 – 3.30
-35.3% YoY
|
3.30
3.30 – 3.30
+0.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
11.65M
OE per share TTM
1.03
Owner's Yield
157.05%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
132.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-79.9K
Shares Outstanding
11.39M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Norton Singhavon | Founder, Chief Executive Officer & Director | 700.0K | male |
| Jeremy Christopher Wright | Chief Financial Officer | 180.0K | male |
| David Buckle | Senior Vice President of Cannabis Operations | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AVNT.TO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
